Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:
“Patina published in NEJM
The addition of palbociclib to maintenance anti-HER2 and endocrine therapies led to a significant improvement in progression-free survival over standard therapy.”
More posts about Breast cancer.